News

The two-year agreement will support intensive laboratory work by a team of research scientists at MD Anderson, who will focus on the novel synthesis and molecular modeling of

The ruling means that the publishing of the private investors’ details or any further contact with them is now prohibited by law, and that anybody who found to

Cymbalta is already approved in the US for the treatment of major depressive disorder and the management of diabetic peripheral neuropathic pain, both in adults. Lilly is also

The in-licensed technology may enable small interfering RNAs – or siRNAs, the molecules that mediate RNAi – to be targeted with an engineered monoclonal antibody to tumors and

The companies aim to create novel, localized treatments that stop tumor re-growth after surgery through the direct application of a combined biomaterial/anticancer therapeutic at the site of tumor

Aradigm’s liposomal ciprofloxacin is an aerosolized formulation of this proven anti-infective drug that was designed to increase the drug’s residence time in the lung and prolong its anti-infective

Merck will acquire 100% of the equity of GlycoFi in an all cash transaction valued at approximately $400 million. GlycoFi is a privately held biotechnology company focused in

Study data showed no statistically significant difference between ALS-02 5g per day and placebo with regard to the study’s primary and secondary endpoints, which consisted of various measures

Maxygen achieved this latest milestone by developing a manufacturing process for the product candidates. Factor VII is a natural protein with a pivotal role in blood coagulation and